Health policy experts say the tariffs would raise prices for patients, potentially disrupt supply, and could hurt the US manufacturers who need ingredients from other countries.

Mehmet Oz recently took the reins as the new head of the Centers for Medicare & Medicaid Services (CMS), which oversees health coverage for nearly half of Americans. He will ...

Mehmet Oz recently took the reins as the new head of the Centers for Medicare & Medicaid Services (CMS), which oversees health coverage for nearly half of Americans. He will ...

CMS’ drug price negotiations are advancing, but new indications and exclusivity rules could complicate future pricing cycles. CMS gained the authority to negotiate list prices with drug manufacturers ...

Giving small-molecule drugs the same 13-year exemption from price negotiation as biologics would cost the federal government billions of dollars, argue three Harvard researchers ...

The proposal should be withdrawn. It is untethered to the Inflation Reduction Act and science and undercuts the incentive to ...

Key pharma reforms are up in the air as Republicans battle over their mammoth legislation that includes significant ...

This could force many local pharmacies to choose between stocking critical medications or keeping their doors open.

In the shadow of President Trump's efforts to lower drug prices, the Medicare drug price negotiation process that began in ...

CMS draft guidance includes Medicare Part B drugs in 2026 price negotiations ... extends similar rules for Part D drugs through 2028. The first round of negotiations, covering 10 Part D drugs ...

or about 14% of Medicare Part D’s prescription drug costs, according to CMS. The negotiated prices for the drugs will take effect in 2027. The second round of negotiations builds on the success ...

The Trump administration signaled Medicare drug price negotiations under the Inflation ... not total [Medicare parts B and D] spending,” Holz-Eakin told Health Care News. Under the IRA, CMS has the ...